논문 목록
5건-
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
[INTRODUCTION] The ORCHARD (NCT03944772) study was conducted to characterize resistance mechanisms and identify optimal treatments after progressive disease (PD) on first-line osimertinib. We report results from the osimertinib plus savolit…
-
Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), alone or as part of combination regimens, remain the standard first-line treatment for patients with EGFR-mutation positive (EGFRm-positive) advanced non-small-cell …
- Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.
-
Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States.
[INTRODUCTION] Chemoimmunotherapy with atezolizumab or durvalumab has been the standard-of-care first-line (1L) treatment for extensive-stage small cell lung cancer (ES-SCLC) in the United States (US) since 2019. However, real-world evidenc…
-
Sevabertinib in Advanced -Mutant Non-Small-Cell Lung Cancer.
[BACKGROUND] gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models. [METHODS] We conducted…